<DOC>
	<DOCNO>NCT00036959</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ABT-751 , work different way stop tumor cell divide stop grow die . PURPOSE : This phase I trial study side effect ABT-751 treat young patient refractory solid tumor .</brief_summary>
	<brief_title>ABT-751 Treating Young Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose dose-limiting toxic effect ABT-751 administer daily 7 day every 21 day daily 21 day every 28 day child refractory solid tumor . - Determine toxicity spectrum regimens patient . - Determine pharmacokinetics regimens patient . - Evaluate pharmacodynamics drug measure fraction tubulin polymerize peripheral blood mononuclear cell patient receive drug . Secondary - Quantify responses patient treat regimen . - Assess effect drug tumor vascularity tumor blood flow use dynamic enhanced MRI patient . OUTLINE : This open-label , multicenter , dose-escalation study 2 different schedule ABT-751 . Patients assign 1 2 dosing schedule . - Schedule 1 ( close accrual 5/25/2009 ) : Patients receive oral ABT-751 daily day 1-7 . Courses repeat every 21 day absence disease progression unacceptable toxicity . - Schedule 2 ( close accrual 5/25/2009 ) : Patients receive oral ABT-751 daily day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . On schedule , cohorts 3-6 patient receive escalate dos ABT-751 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Once MTD determine , 9 patient ( minimum 3 patient age 11 3 patient age 12 18 ) treat MTD . PROJECTED ACCRUAL : A maximum 90 patient accrue study within 8 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor* , include , limited , follow : Rhabdomyosarcoma Other soft tissue sarcomas Ewing 's sarcoma family tumor Osteosarcoma Neuroblastoma Wilms ' tumor Hepatic tumor Germ cell tumor Primary brain tumor Brain stem optic glioma ( histological confirmation may waive biopsy perform ) NOTE : *Closed accrual diagnosis except neuroblastoma 4/16/05 Relapsed fail respond frontline standard therapy standard treatment option ( e.g. , surgery , radiotherapy , chemotherapy , combination modality ) exist Measurable evaluable disease* NOTE : *Not required patient neuroblastoma No CNS tumor motor sensory deficit would obscure study assessment sensory neuropathy PATIENT CHARACTERISTICS : Age : 18 Performance status : Lansky 60100 % ( age 10 ) Karnofsky 60100 % ( age 11 18 ) Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT AST great 2.5 time ULN ( 5 time ULN patient treat maximum tolerated dose determine ) No clinically significant hepatic dysfunction Renal : Creatinine normal age OR Creatinine clearance least 60 mL/min No clinically significant renal dysfunction Cardiovascular : LVEF normal echocardiogram Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No allergy sulfacontaining medication No clinically significant unrelated systemic illness ( e.g. , organ dysfunction ) would preclude study participation No serious infection No preexisting grade 2 great sensory motor neuropathy HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 month since prior bone marrow transplantation At least 72 hour since prior interleukin11 At least 72 hour since prior colonystimulating factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) except epoetin alfa No concurrent growth factor ( e.g. , GMCSF ) except epoetin alfa Concurrent GCSF allow neutropenia last longer 5 day OR patient experience confirm septicemia associate neutropenia No concurrent immunotherapy No concurrent interleukin11 Chemotherapy : See Disease Characteristics At least 30 day since prior chemotherapy ( 42 day nitrosoureas ) No concurrent anticancer chemotherapy Endocrine therapy : Patients brain tumor : Must stable taper dose corticosteroid 7 day baseline scan perform purpose assess response study therapy Concurrent corticosteroid allow control symptom tumorassociated edema Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy At least 4 month since prior extensive radiotherapy ( craniospinal radiotherapy , total body irradiation , radiotherapy 50 % pelvis ) No concurrent radiotherapy Surgery : See Disease Characteristics Other : Recovered prior therapy At least 30 day since prior investigational anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>stage IV Wilms tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>childhood germ cell tumor</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>childhood teratoma</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>childhood malignant ovarian germ cell tumor</keyword>
	<keyword>childhood extragonadal germ cell tumor</keyword>
	<keyword>recurrent childhood malignant germ cell tumor</keyword>
</DOC>